About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study) | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT02578693

Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)

The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (D...

Lead sponsor: Humanity and Health Research Centre•3 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Humanity and Health Research Centre

Collaborators

Beijing 302 Hospital
Nanfang Hospital, Southern Medical University
Yamanashi Prefectural Central Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients with chronic hepatitis C treated with interferon-based therapy or direct-acting agents (DAAs)-based regimen;
•Provide written, informed consent;
•Be willing and able to comply with the visit schedule and protocol-mandated procedures.

Exclusion Criteria

•Individuals planning to start a new course of hepatitis C therapy including any investigational drug or device during the course of the follow-up time frame;
•History of clinically significant illness or any other major medical disorder that may interfere with follow up, assessments, or compliance with the protocol.
•Inability to provide written informed consent.

Related studies

TERMINATEDPhase 3

Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

NCT01866930 · Chronic Hepatitis C Infection

Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions

NCT02333292 · Chronic Hepatitis C Infection

COMPLETEDPhase 3

A Study to Evaluate Chronic Hepatitis C Infection

NCT01716585 · Chronic Hepatitis C Infection

COMPLETEDPhase 3

A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection

NCT01833533 · Chronic Hepatitis C Infection

COMPLETEDPhase 3

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

NCT02219503 · Chronic Hepatitis C Infection, Compensated Cirrhosis

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 24, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment1,210

Start dateMay 2015

Last updatedMar 24, 2025

Condition

Chronic Hepatitis C Infection

Locations shown

Liver Fibrosis Diagnosis and Treatment Centre, 302 Hospital

Beijing, Beijing Municipality

Humanity and Health GI and Liver Centre

Hong Kong, Hong Kong

Yamanashi Prefectural Central Hospital

Kofu, Yamanashi

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 24, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions